Results 81 to 90 of about 1,460,022 (262)

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Identification of patients with moderate medically unexplained physical symptoms in primary care with a five years follow-up

BMC Family Practice, 2019
Background Patients with medically unexplained physical symptoms (MUPS) are common in primary care, with a spectrum from mild to moderate and chronic MUPS.
Paula Elisabeth van Westrienen, Martijn Frits Pisters, Cindy Veenhof, Nicolaas Johannes de Wit   +3 more
doaj   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Investigation of Mental Health in Patients with Medically ‎Unexplained Physical Symptoms‎

Iranian Journal of Psychiatry, 2016
Objective: Medically unexplained symptoms are physical symptoms, which cannot be explained by organic ‎causes. This study aimed to investigate mental health in patients with medically unexplained ‎physical symptoms.
Frough Riahi, Maryam Izadi-mazidi, Niloufar Khajeddin, Shahriar Nasirzadeh, Fatemeh Shafieian, Ammar Helalinasab, Mozhgan Deilamani   +6 more
doaj  

The integrated Lei‐CNS PBPK‐PD model effectively predicts clozapine brain disposition and D2 receptor occupancy in humans

British Journal of Clinical Pharmacology, EarlyView.
Aim Clozapine, used for treatment‐resistant schizophrenia, has a narrow therapeutic window and highly variable plasma pharmacokinetics (PK), necessitating careful monitoring. Direct measurement of unbound brain PK in humans is unethical. To develop a physiologically based pharmacokinetic–pharmacodynamic (PBPK‐PD) model to predict clozapine brain ...
Mengxu Zhang, Thomas I. F. H. Cremers, Vivi Rottschäfer, Elizabeth C. M. de Lange   +3 more
wiley   +1 more source

A scoping review of treatment for factitious disorder (imposed on self)

Psychiatry Research Communications
Introduction: Factitious disorder imposed on self (FDIS) has a deleterious impact on sufferers through the sequalae of induced illness as well as the consequences of unnecessary investigations and treatments.
Rose Kong Liu, Jessica Green, Richard Newton   +2 more
doaj   +1 more source

Predictors of Persistent Medically Unexplained Physical Symptoms: Findings From a General Population Study

Frontiers in Psychiatry, 2018
Objective: To explore the persistency of Medically Unexplained Symptoms (MUS) and its prognostic factors in the general adult population. Knowledge of prognostic factors of MUS may indicate possible avenues for intervention development.Methods: Data were
Jonna F. van Eck van der Sluijs, Jonna F. van Eck van der Sluijs, Margreet ten Have, Ron de Graaf, Cees A. Th. Rijnders, Harm W. J. van Marwijk, Christina M. van der Feltz-Cornelis, Christina M. van der Feltz-Cornelis, Christina M. van der Feltz-Cornelis   +8 more
doaj   +1 more source

"Reattribution for medically unexplained symptoms": Authors' reply

, 2008
Reply to the commentary Reattribution for medically unexplained symptoms by Hiske J. van Ravesteijn, Peter L. B. J. Lucassen, and Tim C. olde Hartman, (see record 2008-05194-021) on the current authors' original article Randomised controlled trial of ...
Morriss, Richard K.
core   +1 more source

Adaptive imatinib regimens can mitigate cumulative toxicity while sustaining hemodynamic benefit: A model‐based simulation of the positioning imatinib for pulmonary arterial hypertension trial

British Journal of Clinical Pharmacology, EarlyView.
ABSTRACT Aims Imatinib improves hemodynamics in pulmonary arterial hypertension (PAH), but dose‐dependent toxicity has limited its clinical development. We aimed to quantify the dose–efficacy–toxicity relationship and evaluate alternative dosing strategies using data from the PIPAH trial.
Medhat M. Said, Robert B. de Mooij, Dian Jiao, Reitze J. Ovelgonne, Rami Biram, Juan Delgado‐SanMartin, Alexander M. K. Rothman, Sofia S. Villar, Andreas A. Roussakis, Jurjan Aman, Ron A. A. Mathôt, Eleonora L. Swart, Martin R. Wilkins, Imke H. Bartelink   +13 more
wiley   +1 more source

Medically unexplained symptoms: how often and why are they missed?

, 2000
We assessed risk factors affecting the provisional diagnosis of medically unexplained symptoms made by physicians in new patients, in 526 clinical encounters. Comparisons were made between the doctor's initial assessments regarding the nature of symptoms,
Wessely, S; id_orcid, Hotopf, M, Nimnuan, C   +2 more
core   +1 more source